Howard Horn Sells 3,061 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $23.56, for a total transaction of $72,117.16. Following the completion of the transaction, the chief financial officer directly owned 88,935 shares in the company, valued at approximately $2,095,308.60. This represents a 3.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Howard Horn also recently made the following trade(s):

• On Wednesday, December 10th, Howard Horn sold 3,081 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $36.38, for a total transaction of $112,086.78.

Ultragenyx Pharmaceutical Trading Down 0.4%

NASDAQ:RARE opened at $24.69 on Thursday. The firm has a market capitalization of $2.38 billion, a PE ratio of -4.16 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 1 year low of $18.41 and a 1 year high of $46.50. The firm’s fifty day simple moving average is $28.52 and its 200 day simple moving average is $29.93.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The firm had revenue of $159.93 million for the quarter, compared to analyst estimates of $167.42 million. During the same period in the prior year, the firm earned ($1.40) EPS. The firm’s revenue was up 14.6% on a year-over-year basis. As a group, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of RARE. Covestor Ltd boosted its holdings in shares of Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 369 shares during the period. Huntington National Bank lifted its position in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 393 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in Ultragenyx Pharmaceutical by 1.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock worth $828,000 after purchasing an additional 404 shares during the period. Xponance Inc. boosted its stake in Ultragenyx Pharmaceutical by 3.1% in the 3rd quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock worth $406,000 after purchasing an additional 406 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Ultragenyx Pharmaceutical by 2.3% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock worth $690,000 after purchasing an additional 434 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Wall Street Analysts Forecast Growth

RARE has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 21st. Wells Fargo & Company dropped their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 30th. Guggenheim cut their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research note on Monday, January 5th. Truist Financial decreased their price target on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Finally, Jefferies Financial Group cut their price objective on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a research report on Tuesday, December 30th. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $72.29.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Long‑term UX111 gene therapy data and regulatory progress — Ultragenyx published up to 8.5 years of follow‑up showing sustained, meaningful clinical benefit for UX111 (rebisufligene etisparvovec) in MPS IIIA and said it resubmitted the BLA to the U.S. FDA in January 2026 with an expected review period of up to six months. This materially improves the odds of near‑term regulatory clarity and eventual commercial upside if approved. Ultragenyx announces positive longer-term UX111 data
• Positive Sentiment: Analyst support — HC Wainwright reaffirmed a “buy” rating and a $60 price target, highlighting upside (~+143% vs. current levels) and giving investors a bullish valuation benchmark to weigh against recent weakness. HC Wainwright rating coverage
• Neutral Sentiment: Insider selling by the CFO — CFO Howard Horn sold 3,061 shares (~$72k) on Feb 2; this reduces his stake by ~3.3% but leaves substantial remaining ownership. Small dollar amount relative to market cap suggests limited direct financial implication, though markets sometimes interpret insider sales as a weak signal. CFO insider sale details
• Negative Sentiment: Class action filings and investigations — Robbins Geller Rudman & Dowd announced a proposed class action covering purchases from Aug 3, 2023 to Dec 26, 2025, alleging securities law violations. Litigation risk can increase volatility, potential legal costs, and management distraction. RGRD class action notice
• Negative Sentiment: Additional securities‑fraud notices — Robbins LLP issued an investor notice about a related securities class action, signaling multiple firms are investigating/filing claims; this reinforces legal risk and could pressure sentiment until resolved. Robbins LLP investor notice
• Negative Sentiment: Pomerantz investigation — Pomerantz LLP is also investigating claims on behalf of Ultragenyx investors, adding to the number of law firms reviewing potential litigation matters; more filings or consolidation of suits could follow. Pomerantz investigation notice

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.